T-knife Therapeutics Announces Upcoming Data Presentations
T-knife Therapeutics, Inc. will present four posters on TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
The posters will review product characterization and manufacturing data on TK-6302, a PRAME T cell receptor therapy advancing towards the clinic.
- TK-6302 targets PRAME, a validated target expressed in various cancers, including skin, uterus, ovaries, lungs, breasts, esophagus, kidneys, cervix, and head & neck.
- A Clinical Trial Application for TK-6302 is planned for Q4 2025.
PRAME is a validated target and is expressed in cancers of the skin, uterus, ovaries, lungs, breasts, esophagus, kidneys, cervix, and head & neck
T-knife Therapeutics develops T cell receptor engineered T cell therapies to fight cancer.
Author summary: T-knife presents TK-6302 data at SITC meeting.